Advertisement

Advertisement
Lung Cancer

Adjuvant Osimertinib ‘Exceeds Expectations’ in Early-Stage EGFR-Positive NSCLC

Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA...

Colorectal Cancer
Immunotherapy

Pembrolizumab Doubles Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer

For the first timeupfront treatment with immunotherapy has improved—in fact, doubled—median progression-free survival...

Bladder Cancer
Immunotherapy

Maintenance Avelumab Improves Survival in Advanced Bladder Cancer

Maintenance therapy with avelu­mab and best supportive care significantly prolonged overall survival vs best supportive care alone...


Advertisement
Hepatobiliary Cancer

Ivosidenib for IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma

As reported by Ghassan K. Abou-Alfa, MD, and colleagues in The Lancet Oncology, the phase III ClarIDHy trial has shown...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Head and Neck Cancer
Survivorship

Pam Baker DeGuzman, PhD, on Assessing Distress During Telemedicine Visits With Rural Survivors of Head and Neck Cancer

Lung Cancer
Immunotherapy

FDA Approves Atezolizumab for the First-Line Treatment of Patients With Metastatic NSCLC and High PD-L1 Expression

On May 18, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (PD-L1 stained ≥ 50% of tumor cells or...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland

COVID-19
Global Cancer Care

Cancer Care at Tata Memorial Centre During the COVID-19 Pandemic

In correspondence published in The New England Journal of Medicine, two practitioners from Tata Memorial Centre, India’s largest cancer center, describe measures taken to continue providing cancer care during the COVID-19 pandemic in India. As related by the authors, scaling back of operations at...

Lymphoma

Detecting Relapse in Patients With Lymphoma in First Remission: Value of Surveillance Laboratory Testing

In a single-institution retrospective study reported in JCO Oncology Practice, Lynch et al found that routine laboratory surveillance testing had limited value in detecting relapse in patients with classical Hodgkin lymphoma in first remission. Study Details The study involved 235 patients at...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19

Lung Cancer
Genomics/Genetics

Germline Genetic Variants in ATM and Lung Cancer Susceptibility

An international consortium of researchers has identified a mutation involved in a person’s susceptibility to lung cancer. This variant could help identify certain populations at greater risk for lung cancer, according to results reported by Ji et al in Nature Communications. ATM Variant Their...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...